Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III study showcasing the efficacy of its anti-PD-L1 drug Tecentriq (atezolizumab) in combination with Exelixis’s (NASDAQ: EXEL) tyrosine kinase inhibitor (TKI) Cabometyx (cabozantinib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study focused on patients with measurable extra-pelvic soft tissue metastasis who had progressed on one prior novel hormonal therapy (NHT). After a median follow-up period of 14.3 months, the combined therapy achieved a median progression-free survival (PFS) of 6.3 months, outperforming the 4.2 months recorded for a second NHT. This represents a 36% reduction in the risk of disease progression or death, successfully meeting the primary endpoint of the study.
However, the co-primary endpoint of overall survival (OS) has not yet reached statistical significance. The current OS figures stand at 16.7 months for the Tecentriq and Cabometyx combination and 14.6 months for the second NHT. The research team intends to conduct the next OS analysis later this year.- Flcube.com
